From scaling new cancer treatment approaches to expanding personalized medicine and developing smarter diagnostic tools, this week’s MedTech financings show continued investor confidence in technologies addressing major clinical challenges. Here’s the rundown.
Leo Cancer Care raises $65M Series D to scale upright cancer care platform
Leo Cancer Care has raised $65M in a Series D round led by Yu Galaxy, with participation from Eventide Asset Management and existing investors. The funding will support manufacturing scale-up, commercial deployment and clinical development of its integrated upright cancer care platform, combining proton therapy, photon therapy and imaging. The investment follows Stanford Medicine’s first compact upright proton therapy treatment using Leo’s Marie platform, designed to reduce infrastructure requirements and expand access to advanced radiation therapy.
CEO and Co-Founder Stephen Towe: “What began as a vision to improve radiation therapy has evolved into something much broader.”
Last week’s tracker: Lumitron, Nanoflex Robotics & more
CurifyLabs raises $14M Series A to expand personalized medicine platform
CurifyLabs has raised $14M in a Series A round co-led by Sandwater and HealthCap, with participation from Tesi and existing investors. The funding will support U.S. expansion, supply chain development and R&D for its Compounding System Solution, which combines software, GMP-manufactured excipients and 3D printing technology to automate personalized medication production.
CEO and Founder Charlotta Topelius: “We have set a high bar for clinical rigor, product quality, and customer support, and this funding gives us the resources to raise that bar further.”
Fibroheal raises Rs. 14 crore to expand silk-based wound care solutions globally
Fibroheal has raised Rs. 14 crore from existing investors to scale operations, strengthen commercial capabilities and expand into international markets. The funding will support regulatory readiness and development of its silk biomaterial-based wound care technologies, which are currently used across 500+ hospitals in India and have treated over 150,000 patients.
CEO Vivek Mishra: “This funding positions us to strengthen our global footprint while advancing various biomaterials-based breakthrough technologies that addresses significant clinical needs.”
Respiro Diagnostics secures £1M to advance lung diagnostics
Respiro Diagnostics has raised £1M in a pre-seed round led by Zinc Venture Capital and SFC Capital, with participation from Amadeus Capital Partners and others. The funding will support clinical research and development of its non-invasive breath-based liquid biopsy platform, which analyses DNA, RNA and proteins from exhaled breath for lung cancer and respiratory disease detection.
CEO and Co-Founder Alison Quinn: “Our vision is simple: that one day, a breath sample is all it takes to know what’s happening in your lungs — early, while there’s still time to act.”
BioTube raises Series A funding to advance regenerative wound care device
BioTube has secured Series A investment from MedVenture Partners’ MPI fund and DBJ Capital to advance its iBTA®-based Biococktail Tissue Modulator (BCM), a medical device designed to regenerate tissue by forming aggregates of patients’ own bioactive components, including pluripotent stem cells. The funding will support clinical development and regulatory approval efforts for treating severe diabetic foot ulcers and gangrene.
President and CEO Shinji Yano
